Skip to main content

Table 3 Changes in parameters related to IDH

From: Effects of hydrophilic polymer-coated polysulfone membrane dialyzers on intradialytic hypotension in diabetic hemodialysis patients (ATHRITE BP Study): a pilot study

  NV group PS/PES group P
Pre-dialysis body weight (kg)
 Pre-observation period (zero month) 66.7 ± 17.5 67.7 ± 12.4 0.84
 First month 66.7 ± 17.4 67.9 ± 12.4 0.81
 Second month 66.7 ± 17.5 67.8 ± 12.4 0.83
 Third month 66.9 ± 17.6 68.1 ± 12.6 0.80
 Fourth month 66.8 ± 17.6 68.0 ± 12.5 0.81
 Fifth month 66.6 ± 17.6 67.8 ± 12.7 0.81
 Sixth month 66.6 ± 17.5 68.1 ± 13.1 0.76
Ultrafiltration volume (ml/session)
 Pre-observation period (zero month) 3071 ± 1134 3163 ± 996 0.79
 First month 3014 ± 1173 3066 ± 985 0.88
 Second month 2939 ± 1168 2988 ± 964 0.89
 Third month 2949 ± 1201 3129 ± 1015 0.61
 Fourth month 2995 ± 1171 3015 ± 1005 0.95
 Fifth month 3023 ± 1305 2956 ± 1020 0.86
 Sixth month 3028 ± 1202 3134 ± 1018 0.77
Cardiothoracic ratio (%)
 Pre-observation period (zero month) 50.1 ± 4.9 50.7 ± 5.3 0.72
 Sixth month 51.4 ± 4.5 52.1 ± 5.6 0.69
Antihypertensive drug users (%)
 Pre-observation period (zero month) 16 (80%) 9 (45%) 0.02
  ARB (8) ARB (5)  
Ca antag. (13) Ca antag. (4)
β blocker (3) β blocker (3)
α blocker (1) α blocker (1)
αβ blocker (1) αβ blocker (2)
 Sixth month 17 (85%) 10 (50%) 0.02
  ARB (7) ARB (6)  
Ca antag. (13) Ca antag. (5)
β blocker (1) β blocker (4)
α blocker (3) α blocker (1)
αβ blocker (1) αβ blocker (2)
Antiplatelet/anticoagulant users (%)a
 Pre-observation period (zero month) 14 (82%) 17 (100%) 0.23
  Aspirin (12) Aspirin (15)  
Clopidogrel (1) Clopidogrel (2)
Warfarin (0) Warfarin (3)
EPA (0) EPA(0)
O3FAE (0) O3FAE (0)
Other (3) Other (6)
Statin (1) Statin (3)
 Sixth month 14 (82%) 17 (100%) 0.23
  Aspirin (12) Aspirin (15)  
Clopidogrel (3) Clopidogrel (3)
Warfarin (1) Warfarin (2)
EPA (0) EPA (0)
O3FAE (0) O3FAE (0)
Other (3) Other (7)
Statin (1) Statin (3)
  1. ARB angiotensin receptor blocker, Ca antag. calcium antagonist, EPA Epadel, O3FAE, Omega-3-fatty acid ethyl esters, Other Other antiplatelet/anticoagulant
  2. a n = 17 in both NV and PS/PES groups